NC Biomatrix recieves MIT Haalbaarheid Grant 2021

Yesterday NC Biomatrix was awarded an MIT Haalbaarheid Grant 2021 to support the feasibility study for a further NC Biomatrix product to address the major market of knee pain due to osteoarthritis.

Bob Guilleaume, CEO of NC Biomatrix, commented „ We are very grateful for the support of MIT to initiate the development process for a further NC Biomatrix product. Knee osteoarthritis is a massive problem resulting in major societal costs and a reduction in the quality of life. Having a simple injectable curative treatment option for these patients would be a major breakthrough.“